|
Market Closed -
Nasdaq
00:00:00 24/12/2024 +03
|
5-day change | 1st Jan Change | ||
| 0.2531 USD | +4.20% |
|
-.--% | - |
| 07-23 | Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million. | CI |
| 07-23 | Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell | MT |
Stock exchange
Performance
| 1 day | +4.20% | ||
| 3 years | -87.15% |
Volumes
marketsCapital turnover ratio
0
Float rotation
0
Basic data
Market Cap (USD)
20,375,157
Net sales (AUD)
23,791,860
Net sales (USD)
17,149,759
Number of employees
8
Sales / Employee (AUD)
2,973,983
Sales / Employee (USD)
2,143,720
Free-Float
92.76 %
Free-Float capitalization (USD)
18,805,582
Indicators
Moving average 5 days
0.2562
Moving average 100 days
0.4244
Price spread / (MMA5)
+1.22%
Price spread / (MMA100)
+67.68%
STIM
RSI 9 days
0
RSI 14 days
0
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +4.20% | -.--% | -.--% | -87.15% | 20.38M | ||
| -2.54% | -2.84% | -1.90% | +14.52% | 48.93B | ||
| -0.40% | +1.03% | +439.20% | +499.20% | 45.01B | ||
| -1.42% | +2.30% | +45.46% | +19.36% | 44.07B | ||
| -1.22% | -2.31% | +12.40% | +71.48% | 40.73B | ||
| +0.53% | -1.36% | +16.04% | +48.23% | 33.52B | ||
| -0.21% | +9.14% | - | - | 17.77B | ||
| -0.35% | -1.56% | +22.59% | +116.19% | 16.5B | ||
| -1.01% | +0.50% | +15.83% | +27.98% | 14.67B | ||
| -1.65% | -1.03% | +77.75% | +37.63% | 13.77B | ||
| Average | -0.41% | +0.53% | +69.71% | +83.05% | 27.5B | |
| Weighted average by Cap. | -1.03% | +0.11% | +94.85% | +122.10% |
Historical Quotes: BIONOMICSSADR
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Price Extremes
| 3 years | 0.18 | 6.41 | |
| 5 years | 0.18 | 22 | |
| 10 years | 0.18 | 22 |
Monthly variations
Annual variations
| 2024 | -82.90% | ||
| 2023 | -68.17% | ||
| 2022 | -62.95% | ||
| 2021 | -14.80% |
- Stock Market
- Stocks
- NEUP Stock
- BNOX Stock
- Quotes BIONOMICSSADR
Select your edition
All financial news and data tailored to specific country editions

















